BAY2433334 matching placebo
Sponsors
Bayer
Conditions
Acute Myocardial InfarctionAcute Non-cardioembolic Ischemic StrokeAtrial Fibrillation (AF)
Phase 2
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
CompletedNCT04218266
Start: 2020-01-30End: 2021-10-08Updated: 2022-10-27
Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.
CompletedNCT04304508
Start: 2020-06-15End: 2022-02-18Updated: 2023-04-19
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack
CompletedNCT04304534
Start: 2020-06-17End: 2022-02-21Updated: 2023-04-05